14
Participants
Start Date
September 30, 2012
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
"Sirolimus and Hydroxychloroquine 200 mg"
"This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily."
"Sirolimus and Hydroxychloroquine 400 mg"
Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
Brigham and Women's Hospital, Boston
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Brigham and Women's Hospital
OTHER